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As the prevalence of Alzheimer disease (AD) continues to rise unabated, new models
have been put forth to improve our understanding of this devastating condition. Although
individual models may have their merits, integrated models may prove more valuable.
Indeed, the reliable failures of monotherapies for AD, and the ensuing surrender of
major drug companies, suggests that an integrated perspective may be necessary if
we are to invent multifaceted treatments that could ultimately prove more successful.
In this review article, we discuss the Wnt/Glycogen Synthase Kinase 3β (GSK3β),
α-synuclein, and type 3 diabetes hypotheses of AD, and their deep interconnection,
in order to foster the integrative thinking that may be required to reach a solution for the
coming neurological epidemic.
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INTRODUCTION
Alzheimer disease (AD) is among the most ominous of modern health epidemics. The current
costs, both human and financial, are staggering and climbing at a precipitous rate. In the United
States alone, 5.5 million adults live with AD, imposing an economic burden of $259 billion
(Alzheimer’s Association, 2017). Over the next three decades, the number of people living with
AD is expected to triple to 13.8 million and the economic costs are projected to quadruple to
$1.1 trillion, single-handedly crippling the United States health care system. AD is also the only
disease on the list of the top 10 disease causes of death for which there is currently no effective
treatment (Alzheimer’s Association, 2017).
AD is not alone in its ascent. Other chronic diseases, particularly Parkinson’s disease (PD),
a neurodegenerative disorder associated with the build-up of α-synuclein protein and death
of dopaminergic neurons, and type 2 diabetes mellitus (T2DM) are increasing in prevalence
at similarly alarming rates (Boyle et al., 2010; Rocca, 2018). Although AD, PD, and T2DM
share common risk factors, chief among these being age, there is more to their relationship.
Evidence suggests that the pathophysiological mechanisms underlying AD, PD, and T2DM interact
synergistically (Giasson et al., 2003; de la Monte and Wands, 2008; Duka et al., 2009; Wills et al.,
2010; Gao et al., 2012; Ga̧ssowska et al., 2014; Roberts et al., 2017; Yan et al., 2018).
In addition to the well-known amyloid cascade hypothesis of AD, other hypotheses have been
proposed that include: (1) the Wnt/Glycogen Synthase Kinase 3β (GSK3β) hypothesis (Hooper
et al., 2008; De Ferrari et al., 2014; Llorens-Martín et al., 2014), (2) the α-synuclein hypothesis
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(Moussaud et al., 2014; Yan et al., 2018), and (3) the type
3 diabetes hypothesis (de la Monte and Wands, 2008). In
this review article, we focus on the Wnt/GSK3β hypothesis,
describing how it serves as a platform for a set of positive
feedback loops that contribute to the pathogenesis of AD. In turn,
we also discuss the α-synuclein and type 3 diabetes hypotheses,
describing how they each constitute their own feedback loops and
interact with the Wnt/GSK3β model.
WNT/GSK3β
Overview of Wnt-Signaling
Wnt-signaling refers to a set of highly conserved signal
transduction pathways that are widely expressed throughout the
body and that play a vital role both in neuronal development
and in the maintenance of proper neuronal function in the
adult human brain (Patapoutian and Reichardt, 2000; Oliva
et al., 2013; Rosso and Inestrosa, 2013; Nusse and Clevers,
2017). In this article, we focus on the better-studied canonical
Wnt-β-catenin-signaling pathway, leaving the topic of the two
non-canonical Wnt-signaling pathways (the Wnt-planar cell
polarity and Wnt-calcium pathways) for others to discuss in
depth (Mudher et al., 2001; Gao et al., 2012; Oliva et al.,
2013; Rosso and Inestrosa, 2013; Wan et al., 2014). Canonical
Wnt-β-catenin-signaling (hereafter, referred to simply as Wnt-
signaling) is initiated by the binding of Wnt ligands to the
Wnt receptor pair, Low-Density Lipoprotein Receptor-Related
Protein 6-Frizzled (LRP6-Fz). LRP6 then recruits Dishevelled
(DVL), a scaffolding protein that sequesters GSK3β from the
cytoplasm. The inhibition of GSK3β, a constitutively active
kinase that targets the transcriptional cofactor β-catenin for
proteasomal degradation, is central to Wnt-signaling. Simply
put, Wnt-signaling inhibits GSK3β, permitting β-catenin to
accumulate in the cytoplasm and translocate into the nucleus to
mediate the transcription of genes, such as BACE1 and ADAM10
(elaborated upon below), involved in the pathogenesis of AD
(Rosso and Inestrosa, 2013; Figure 1A).
Dysfunctional Wnt-Signaling Causes the
Production of Aβ
Amyloid plaques, aggregates of the amyloid β (Aβ) peptide, are
the primary pathological hallmark of AD. Aβ is formed by the
sequential cleavage of amyloid precursor protein (APP) by β-
and γ-secretase (Figure 1B). This amyloidogenic processing is in
contrast to nonamyloidogenic processing, in which α-secretase
replaces β-secretase and cleaves APP within the Aβ domain such
that no Aβ is produced (Haass et al., 2012; Figure 1A). By altering
α- and β-secretase gene expression, as well as by decreasing
APP phosphorylation, Wnt-signaling shifts APP metabolism
away from amyloidogenic processing and protects against Aβ
neuropathology (Alvarez et al., 2004; Parr et al., 2012; Liu
et al., 2014; De Ferrari et al., 2014; Llorens-Martín et al., 2014;
Wan et al., 2014).
With respect to secretase gene expression, Wnt-signaling
downregulates the sole β-secretase gene, BACE1 (Haass et al.,
2012; Parr et al., 2015), and upregulates the primary neuronal α-
secretase gene, ADAM10 (Haass et al., 2012; Wan et al., 2012).
In APP-overexpressing mice, GSK3β inhibition has been shown
to decrease BACE1 expression and activity, thereby reducing
amyloid plaque load (Ly et al., 2013). Furthermore, in cultured
neurons, activating Wnt-signaling, by using Wnt ligands or
overexpressing β-catenin, is sufficient to increase ADAM10
expression (Wan et al., 2012) and decrease BACE1 expression,
again reducing Aβ levels (Parr et al., 2015). These data are
consistent with a model in which dysfunctional Wnt-signaling in
the AD brain causes GSK3β-mediated β-catenin depletion, which
leads to a pathological decrease in the ratio of α-secretase to
β-secretase expression (Figure 1Bi) and, thus, to an increase in
the amyloidogenic processing of APP to Aβ (Mudher et al., 2001;
Chami et al., 2012; Wan et al., 2012; Ly et al., 2013; De Ferrari
et al., 2014; Llorens-Martín et al., 2014; Wan et al., 2014; Golpich
et al., 2015; Parr et al., 2015).
Wnt-signaling further suppresses amyloidogenic processing
by inhibiting APP phosphorylation. Specifically, Wnt-signaling
inhibits GSK3β, which otherwise phosphorylates APP on Thr668
(Saeki et al., 2011; Acevedo et al., 2014), contributing to the
elevated p-Thr668 APP levels that are observed in the human
AD brain (Lee et al., 2003; Figure 1Bii). The direct consequences
of Thr668 phosphorylation are two-fold. First, p-Thr668 APP is
a better substrate for β-secretase than unphosphorylated APP
(Lee et al., 2003). Second, if the APP intracellular domain
(AICD)—which contains Thr668 and is produced in conjunction
with Aβ by γ-secretase-mediated cleavage—is phosphorylated,
it can translocate into the nucleus to upregulate GSK3β gene
expression (Chang et al., 2006; Figure 1B). In this way,
dysfunctional Wnt-signaling permits the phosphorylation of
APP by GSK3β, leading to both an increase in Aβ production
and an increase in GSK3β expression, establishing a positive
feedback loop.
As predicted by this model, inhibiting Wnt-signaling with the
LRP6 inhibitor, Dicckopf-1 (DKK1), increases the amyloidogenic
processing of APP and impairs learning and memory in mice
(Killick et al., 2012; Parr et al., 2015; Marzo et al., 2016; Elliott
et al., 2018; Sellers et al., 2018), whereas activating Wnt-signaling
with different GSK3β inhibitors decreases BACE1 expression,
decreases APP phosphorylation, decreases Aβ production,
prevents neurodegeneration, and reduces learning and memory
(Ryder et al., 2003; Chang et al., 2006; Rockenstein et al., 2007;
Fiorentini et al., 2010; Toledo and Inestrosa, 2010; Ly et al., 2013;
Pan et al., 2018).
Aβ Causes Dysfunctional Wnt-Signaling
Aβ, in turn, can inhibit Wnt-signaling to establish another
positive feedback loop. Treatment of rat neurons in vitro with
Aβ induces the expression of DKK1 and increases GSK3β
activity, thereby decreasing β-catenin levels and contributing
to the death of neurons (Alvarez et al., 2004; Caricasole
et al., 2004; Killick et al., 2012; Elliott et al., 2018; Sellers
et al., 2018). Importantly, activation of Wnt-signaling via
a variety of mechanisms—by treatment with Wnt ligands,
neutralization of DKK1, or inhibition of GSK3β—appears
sufficient to protect neurons against β-catenin depletion and,
ultimately, death (Alvarez et al., 2004; Caricasole et al., 2004;
Silva-Alvarez et al., 2013).
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FIGURE 1 | Dysfunctions in canonical Wnt-Signaling contribute to the neuropathology of Alzheimer disease (AD). (A) Functional Wnt and Nonamyloidogenic
Processing—Glycogen Synthase Kinase 3β (GSK3β) is a constitutively active kinase that phosphorylates and targets β-catenin for proteasomal degradation. The
binding of Wnt ligands to LDL Receptor-Related Protein 6 (LRP6) and Frizzled induces the receptor pair to bind Dishevelled (DVL), a protein that serves as a docking
platform for GSK3β. The sequestration of GSK3β by the Wnt receptor complex permits β-catenin to accumulate and translocate into the nucleus, where it binds
transcription factors to induce gene expression. This includes promoting anti-amyloidogenic α-secretase expression (blue mRNA) and inhibiting pro-amyloidogenic
β-secretase expression. (B) Dysfunctional Wnt, Amyloidogenic Processing, and Tau Hyperphosphorylation—The LRP6 antagonist, Dickkopf 1 (DKK1), prevents
Wnt-induced GSK3β inhibition (broken red line). Thus, (i) GSK3β causes β-catenin depletion, contributing to a decrease in α-secretase expression and increase in
β-secretase expression (red mRNA). In addition, (ii) GSK3β phosphorylates the intracellular domain of Amyloid Precursor Protein (APP), making APP a better
substrate for β-secretase and further promoting amyloidogenic processing and the production of Amyloid β (Aβ) by β- and γ-secretase. Aβ inhibits Frizzled and
induces DKK1 expression to feedback and prevent GSK3β inhibition (broken red line). Aβ also forms extracellular plaques. The leftover phosphorylated APP
Intracellular Domain (p-AICD) induces GSK3β expression. Finally, (iii) GSK3β, also known as Tau Kinase I, phosphorylates tau, contributing to microtubule instability
and to the formation of neurotoxic oligomers and phospho-tau (p-tau) Neurofibrillary Tangles (NFTs). (C) Human Neuropathological and Genetic Data are Consistent
with the Wnt/GSK3β Model of AD—In the Alzheimer brain, as compared to the healthy aged brain, the levels and activities of Wnt-signaling components are
indicative of pathway hypoactivity: DKK1 levels are elevated, LRP6 levels are reduced, GSK3β activity is high, and β-catenin is depleted. Furthermore, LRP6
loss-of-function and GSK3β gain-of-function alleles are risk factors for AD.
Not only does Aβ indirectly inhibit the initiation
of Wnt-signaling by increasing the expression of the
LRP6 antagonist, DKK1 (Caricasole et al., 2004; Killick
et al., 2012; Purro et al., 2012; Marzo et al., 2016; Elliott
et al., 2018), but it also directly blocks the binding of Wnt
ligands to the other half of the LRP6-Fz receptor pair.
Using cultured mouse neurons, Magdesian et al. (2008)
demonstrated that Aβ competitively inhibits the binding of
Wnt ligands to Fz and, consequently, prevents β-catenin from
translocating into the nucleus to induce Wnt target gene
expression (Figure 1B). Aβ also increases GSK3β activity
leading to neurodegeneration (Alvarez et al., 2004; Caricasole
et al., 2004; Hooper et al., 2008; De Ferrari et al., 2014;
Llorens-Martín et al., 2014; Wan et al., 2014). Importantly,
interventions that either block the interaction between Aβ
and the Wnt receptors, or those that circumvent the Aβ
blockade and activate Wnt-signaling downstream of LRP6-
Fz, protect neurons against Aβ toxicity (Alvarez et al., 2004;
Caricasole et al., 2004; Hooper et al., 2008; Magdesian et al.,
2008; De Ferrari et al., 2014; Llorens-Martín et al., 2014;
Wan et al., 2014). Some examples are as follows: a synthetic
soluble peptide homologous to Fz competitively inhibited
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Aβ binding to Fz and, thereby, protected against β-catenin
depletion (Magdesian et al., 2008); upstream activation of
Wnt-signaling using competitive amounts of exogenous
Wnt ligands (Wnt3a or Wnt7a) prevented Aβ-induced
neuron apoptosis; downstream activation of Wnt-signaling
using multiple different GSK3β inhibitors also prevented
Aβ-induced neurodegeneration (Alvarez et al., 1999, 2004;
Silva-Alvarez et al., 2013).
An LRP6 Deletion Model Supports the
Wnt/GSK3β-Aβ Feedback Loop
An LRP6 deletion mouse model provides further support for the
hypothesis that dysfunctional Wnt-signaling and Aβ constitute
two halves of a positive feedback loop. Liu and coworkers
demonstrated that conditional deletion of LRP6 in mouse
neurons increased levels of β-secretase cleavage products and
precipitated the formation of Aβ plaques, consistent with the
notion that decreased Wnt-signaling promotes the formation
of amyloid pathology. The neuropathological changes were
associated with significant memory deficits, similar to those
exhibited by more common mouse models of AD (Liu et al.,
2014). Importantly, Aβ, in turn, decreased LRP6 expression,
thus validating the positive feedback loop model in which
dysfunctional Wnt-signaling causes an increase in Aβ, and
vice versa.
These mouse data paralleled those from human patients
with AD. Liu et al. not only found (1) lower LRP6 and
β-catenin levels in the post-mortem brains of AD patients
relative to age-matched control brains (Figure 1C), but also
(2) a negative correlation between LRP6 and Aβ levels in these
brains and (3) a positive correlation between LRP6 levels and
Mini-Mental State Examination (MMSE) scores, a test in which
higher scores indicate better cognitive function (Liu et al.,
2014). Thus, the level of Wnt-signaling dysfunction may predict
the degree of neuropathology and cognitive impairment in
AD patients.
Human Neuropathological and Genetic
Data Support the Wnt/GSK3β Model
Not only are LRP6 levels reduced in the post-mortem brains of
AD patients, but DKK1 levels are also elevated (Caricasole et al.,
2004; Oliva et al., 2013; Wan et al., 2014). The simultaneous
decrease in the Wnt receptor (LRP6) and increase in its
inhibitor (DKK1) cooperatively downregulates Wnt-signaling
and increases GSK3β activity in patients’ brains (Leroy et al.,
2007; Hooper et al., 2008; Oliva et al., 2013; Llorens-Martín et al.,
2014; Wan et al., 2014; Lazzara and Kim, 2015). The genetic
data concur. Specifically, a loss-of-functionmutation in LRP6 has
been identified as a risk factor for AD (De Ferrari et al., 2007),
as have gain-of-function mutations in the GSK3β gene (Schaffer
et al., 2008; Figure 1C).
Furthermore, evidence suggests that the strongest known
genetic risk factor for AD in humans, the ApoE4 allele (Liu
et al., 2013), may negatively impact Wnt-signaling. Similar to
Aβ, the ApoE4 protein increases DKK1 expression, binds to the
LRP6-Fz receptor complex, activates GSK3β, and promotes the
amyloidogenic processing of APP (Kim et al., 1998; Cedazo-
Mínguez et al., 2003; Caruso et al., 2006; Chami et al., 2012;
De Ferrari et al., 2014; Wan et al., 2014; Theendakara et al.,
2016). Therefore, there is a case to be made that ApoE4 either
sparks the positive feedback loop between Wnt-signaling and
Aβ, decreases the threshold for the establishment of the feedback
loop, and/or accelerates the rate at which the loop spirals into
life-altering disease.
GSK3β Links Aβ to p-tau
In addition to contributing to the build-up of amyloid plaques,
the first of the two pathological hallmarks of AD, dysfunctional
Wnt-signaling may also contribute to the development of the
second hallmark of AD, phospho-tau (p-tau) Neurofibrillary
Tangles (NFTs). GSK3β, alternatively known as Tau Kinase I, is
thought to be the mechanistic link between Aβ and p-tau (Lucas
et al., 2001; Leroy et al., 2007; Saeki et al., 2011; De Ferrari et al.,
2014; Llorens-Martín et al., 2014). By inhibiting Wnt-signaling,
Aβ increases GSK3β activity (Alvarez et al., 2004; Caricasole et al.,
2004; Hooper et al., 2008; De Ferrari et al., 2014; Llorens-Martín
et al., 2014; Wan et al., 2014). In turn, GSK3β phosphorylates
tau on a set of residues known to be phosphorylated in AD
(Lucas et al., 2001; Leroy et al., 2007; Saeki et al., 2011; De Ferrari
et al., 2014; Llorens-Martín et al., 2014). This results in two
events. First, tau dissociates from microtubules, disabling tau’s
physiological function as a microtubule-associated protein and
thereby contributing to cytoskeleton instability [as an aside, it’s
worth noting that recent data suggest tau functions as more
than just a microtubule-associated protein and that tau loss-of-
function can contribute to a broader array of cellular defects
than previously thought, including brain insulin resistance
(Marciniak et al., 2017)]. Second, hyperphosphorylated tau
aggregates into neurotoxic oligomers that exert further
harmful effects on the cell, such as inducing mitochondrial
dysfunction, oxidative stress, neuroinflammation, and apoptosis
(Götz et al., 2013; Nilson et al., 2017; Shafiei et al., 2017;
Figure 1Biii).
Experiments conducted in two different animalmodels of AD,
GSK3β mice and APP mice, build a strong case for the serial
connection amongst Aβ, GSK3β, and p-tau. First, conditional
overexpression ofGSK3β in the cortices and hippocampi of adult
mice has been shown to reduce levels of nuclear β-catenin and
increase levels of p-tau (Lucas et al., 2001). The GSK3β-induced
increase in p-tau pathology is further associated with an increase
in neuronal apoptosis and performance deficits in the Morris
water maze test of spatial memory (Lucas et al., 2001; Hernández
et al., 2002). Second, mice overexpressing APP have increased Aβ
and p-tau loads, along withmemory deficits. However, inhibition
of GSK3β in these APP mice is sufficient to protect against
p-tau pathology and against cognitive impairment (Rockenstein
et al., 2007). The neuroprotective and anti-p-tau effects of GSK3β
inhibition in the APP mouse model have been replicated by
multiple independent groups (Fiorentini et al., 2010; Pan et al.,
2018). In short, the two murine models suggest that GSK3β/Tau
Kinase I, a central player inWnt-signaling, links the Aβ and p-tau
pathologies of AD.
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α-SYNUCLEIN
Human Neuropathological
and Genetic Data Suggest
Overlapping Pathology Between
AD and PD
Neither AD nor PD are monolithic disease entities; it is likely
that each is composed of several subtypes that have yet to
be effectively characterized. At least some of the putative AD
subtypes overlap in pathology with those of PD, and vice
versa. More than half of patients with AD present with Lewy
bodies, aggregates of α-synuclein that are the PD equivalent
of Aβ plaques (Moussaud et al., 2014; Yan et al., 2018).
Furthermore, α-synuclein is a component of AD plaques
themselves. In fact, the creatively named non-Aβ component
(NAC) of plaques is a fragment of α-synuclein (Uéda et al.,
1993; Jakes et al., 1994). Thus, α-synuclein lesions are present
in the AD brain as distinct Lewy body structures and as part of
amyloid plaques.
Complementarily, classic AD inclusions are observed in the
PD brain. Specifically, in PD patients, p-tau tends to aggregate
in the substantia nigra and other PD-associated brain regions
(Kotzbauer et al., 2004; Wills et al., 2010; Moussaud et al.,
2014; Yan et al., 2018). This presence of p-tau tangles also
correlates with increased GSK3β activity, an observation that
suggests GSK3β may be responsible for tau phosphorylation in
PD, as it is in AD (Duka et al., 2009; Nagao and Hayashi, 2009;
Wills et al., 2010; Golpich et al., 2015; Lazzara and Kim, 2015).
An extension of this logic is that dysfunctional Wnt-signaling
may be a convergence point for the world’s two most common
neurodegenerative disorders.
The genetic evidence also suggests that GSK3β, tau, and
α-synuclein can synergistically interact in neurodegeneration. As
in AD, polymorphisms in the genes that code for GSK3β
and tau (MAPT) are risk factors for PD (Kwok et al.,
2005; Goris et al., 2007; Schaffer et al., 2008; Moussaud
et al., 2014; Golpich et al., 2015). Furthermore, there is
a genetic interaction between MAPT and the α-synuclein
gene (SNCA) in which the high-expression MAPT haplotype
(H1) and a polymorphism in SNCA synergistically increase
PD risk (Goris et al., 2007). Notably, in this study, only
PD patients with the H1/H1 MAPT haplotype went on
to develop PD with dementia, hinting that this may be
an instance in which the pathology and symptoms of
a PD subtype overlap with those more typical of AD
(Goris et al., 2007).
More relevant to this review article, the SNCA gene also
affects AD risk. Some SNCA polymorphisms double the risk
of AD (Matsubara et al., 2001; Wang et al., 2016), whereas
others decrease the risk of AD (Xia et al., 1996). With
respect to the latter, a retrospective study conducted by Xia
et al. (1996) showed that a particular allele in the SNCA
promoter was enriched 4-fold in cognitively healthy ApoE4
carriers as compared to ApoE4 carriers with AD, suggesting
that this SNCA polymorphism has a protective effect against
the strongest known risk factor for AD. This interaction was
dose-dependent as the presence of the SNCA allele decreased
AD risk by 3-fold in ApoE4 heterozygotes and by 10-fold in
ApoE4 homozygotes (Xia et al., 1996). The fact that SNCA
mutations affect AD risk is consistent with the hypothesis that
α-synuclein plays a role in the development of AD, at least in
some instances.
α-Synuclein Induces Amyloid Pathology,
Possibly in a Wnt/GSK3β-Dependent
Manner, and Is in Positive
Feedback With Aβ
Studies using cultured neurons have demonstrated that
either exogenous treatment with α-synuclein or α-synuclein
overexpression is sufficient to increase the production and
secretion of Aβ (Majd et al., 2013; Roberts et al., 2017). One
mechanism by which α-synuclein could increase Aβ levels
is by activating GSK3β, as suggested by mouse experiments
that show that α-synuclein overexpression increases GSK3β
activity (Duka et al., 2009; Golpich et al., 2015). Exactly
how α-synuclein activates GSK3β is a matter that requires
further investigation; however, several lines of in vitro and
mouse data imply that α-synuclein in neurons could induce
GSK3β-activating ROS (Xu et al., 2002; Witt and Flower,
2006; Wakatsuki et al., 2011, 2015; Perfeito et al., 2017;
Figure 2Ai) and decrease the production neuroprotective
canonical Wnt ligands by astrocytes (L’Episcopo et al., 2011,
2013, 2014; Okamoto et al., 2011; Lindström et al., 2017; Liu
et al., 2018; Figure 2Aii; for an excellent review of the role
of Wnt-signaling in neuron-microglia-astrocyte crosstalk in
neurodegeneration, see L’Episcopo et al., 2018). Although
the dominant mechanism by which α-synuclein induces
GSK3β in vivo is unclear, the observation that intracranial
injections of α-synuclein increase β-secretase and Aβ levels
in mice (Roberts et al., 2017) is, at minimum, consistent with
the model presented in Figure 1B and with the hypothesis
that α-synuclein-induced Aβ production is mediated by the
Wnt/GSK3β axis.
In turn, exogenous treatment with Aβ, even at concentrations
as low as 1 µM, has been shown to increase α-synuclein levels
in neurons (Majd et al., 2013). Although the mechanisms by
which Aβ reciprocally induces α-synuclein likewise remains a
gap in the literature, it is worth noting that upregulation of
Wnt-signaling via β-catenin overexpression or GSK3β inhibition
protects PD models from developing α-synuclein pathology
and motor deficits (Yuan et al., 2015; Stephano et al., 2018).
Furthermore, in vitro, Drosophila, mouse, and human data
collectively suggest that GSK3β specifically phosphorylates
Ser129 of α-synuclein (Figure 2A1), a post-translational
modification predominant in Lewy bodies and in the PD brain
that may enhance α-synuclein aggregation and/or neurotoxicity
(Fujiwara et al., 2002; Chen and Feany, 2005; Anderson et al.,
2006; Credle et al., 2015). GSK3β is also a known inhibitor
of autophagy (Parr et al., 2012; Ren et al., 2016; Weikel
et al., 2016), a ubiquitous cellular recycling process required
for the effective clearance of excess α-synuclein (Vogiatzi
et al., 2008; Sato et al., 2018; Figure 2A2). Therefore, it
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FIGURE 2 | α-Synuclein is in positive feedback with the Aβ and tau pathologies of AD. (A) α-Synuclein is in Positive Feedback with Aβ—α-synuclein may induce
oxidative stress and promote astrocytic dysfunction. Thus, perhaps by (i) increasing the levels of cytoplasmic ROS and (ii) decreasing those of extracellular
astrocyte-derived Wnt ligands, α-synuclein activates GSK3β and induces the production of Aβ (for a more comprehensive discussion about the role of Wnt-signaling
in neuron-glia crosstalk in neurodegeneration, see L’Episcopo et al., 2018). In turn, Aβ activates GSK3β, which (1) phosphorylates α-synuclein on Ser129 and (2) may
impair the autophagic clearance of α-synuclein. (B) α-Synuclein is in Positive Feedback with Tau—α-synuclein can (i) bind tau’s microtubule-binding domain, causing
tau to disassociate from microtubules, (ii) recruit GSK3β to tau and, thereby, promote tau hyperphosphorylation, and (iii) directly seed or chaperone the pathological
aggregation of p-tau. Tau can reciprocate by (1) recruiting GSK3β to α-synuclein, thereby permitting pathogenic Ser129 phosphorylation, and by (2) promoting the
aggregation of α-synuclein. Dashed and solid lines indicate regulatory mechanisms that are, respectively, impaired and enhanced in AD.
is plausible that Aβ-induced GSK3β activation (Figure 1B)
completes an α-synuclein-Aβ feedback loop relevant in some
cases of AD.
α-Synuclein, Directly and via GSK3β,
Induces Tauopathy and Is in Positive
Feedback with p-tau
α-synuclein and tau interact directly (Jensen et al., 1999; Yan
et al., 2018). Specifically, α-synuclein binds tau within tau’s
microtubule-binding domain (Jensen et al., 1999). Even were
this interaction not sufficient to cause tau to disassociate
from microtubules, the binding of α-synuclein to tau induces
the phosphorylation of tau on Ser262, a post-translational
modification observed in the AD brain that causes tau to release
from microtubules, contributing to cytoskeleton instability
(Jensen et al., 1999). Subsequently, α-synuclein can serve as a
necessary cofactor to help p-tau form oligomers and, eventually,
tangles (Giasson et al., 2003; Cremades et al., 2012). Thus, as
reviewed by Moussaud et al. (2014), there are at least three ways
by which α-synuclein can instigate and aggravate tauopathy: by
blocking the interaction between tau and microtubules, thereby
interfering with tau’s physiological function (Figure 2Bi), by
recruiting kinases that promote tau hyperphosphorylation
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(Figure 2Bii), and by seeding or chaperoning the
aggregation of tau into neurotoxic oligomers and
fibrils (Figure 2Biii).
With regard to the kinase mechanism listed above,
GSK3β/Tau Kinase I may play a particularly important role
in the relationship between α-synuclein and tau. Not only does
α-synuclein interact with tau, but both proteins also interact
with, and are phosphorylated by, GSK3β (Duka et al., 2009;
Credle et al., 2015). Thus, α-synuclein can recruit GSK3β to tau,
leading to tau hyperphosphorylation (Figure 2Bii). As this model
predicts, exogenous treatment of cultured cells with α-synuclein
increased levels of p-tau, this phenomenon being blocked by the
inhibition of GSK3β (Ga̧ssowska et al., 2014). Similar findings
have been produced in mice in which the overexpression of
α-synuclein is sufficient to induce GSK3β-mediated p-tau
pathology (Duka et al., 2009). Reflecting on the stimulatory
effect of α-synuclein on GSK3β, as well as that of Aβ on GSK3β
(Figure 1B), we can elaborate upon our model: GSK3β can be
conceptualized as the convergence point of a Y-shaped cascade
in which either Aβ or α-synuclein can activate and/or recruit
GSK3β to induce tau pathology.
Similar to the mutualistic case of Aβ and α-synuclein,
p-tau can promote α-synuclein pathology (Giasson et al.,
2003; Badiola et al., 2011; Yan et al., 2018). Using multiple
different cell models, Badiola et al. (2011) demonstrated
that tau enhanced the aggregation of α-synuclein. In these
experiments, tau overexpression also reduced cell viability in an
α-synuclein-dependent manner (Badiola et al., 2011), perhaps
by promoting the GSK3β-mediated neurotoxic phosphorylation
of α-synuclein on Ser129 (Fujiwara et al., 2002; Chen
and Feany, 2005; Anderson et al., 2006; Credle et al.,
2015), and promoted the secretion of α-synuclein (Badiola
et al., 2011). Thus, tau can complete an intracellular positive
feedback loop with α-synuclein, possibly by facilitating the
pathogenic phosphorylation of α-synuclein Ser129 by GSK3β
(Figure 2B1) and/or by promoting α-synuclein’s aggregation
(Figure 2B2), and tau might also support the prionic cell-
to-cell propagation of α-synuclein (not shown in Figure 2).
Independent of the exact mechanisms, the relevance of
tau on α-synuclein pathology and its attending symptoms
has been demonstrated in vivo. In mice, the transgenic
expression of tau enhances the formation of α-synuclein
inclusions and the corresponding Parkinsonian phenotype
(Giasson et al., 2003).
TYPE 3 DIABETES
Overview of Insulin Signaling and Its Role
in the Brain
Several lines of evidence suggest that, in the central
nervous system, insulin does much more than promote
glucose uptake. Insulin is a neuromodulator, affecting the
reuptake and production of particular neurotransmitters
(Schulingkamp et al., 2000; Plum et al., 2005); insulin
regulates food intake and reproduction by acting on the
hypothalamus to alter endocrine system function (Plum
et al., 2005); and, glucose transport into neurons is largely
insulin-independent. Building upon this last key piece of
evidence, neuron energy utilization also correlates poorly
with the heterogeneous distribution of Insulin Receptor
(IRs) throughout the brain, further suggesting that insulin’s
primary functions in the brain include more than glucose
uptake (Schulingkamp et al., 2000). And, although IRs are
also concentrated in the hypothalamus, olfactory bulb, and
cerebellum, it’s notable that IRs are particularly densely
packed in the hippocampus and cerebral cortex, two brain
regions important in learning and memory that are critically
impacted by AD (Marks et al., 1990; Schulingkamp et al., 2000;
Plum et al., 2005).
The insulin signaling cascade is initiated when insulin
binds to the IR, a heterotetrameric receptor tyrosine kinase
that autophosphorylates in order to recruit the adaptor
protein IR Substrate (IRS). IRS subsequently recruits and
activates Phosphoinositide 3-Kinase (PI3K), a lipid kinase that
generates the second messenger Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). PIP3 can diffuse along the membrane to
activate Phosphoinositide-Dependent Kinase 1 (PDK1), which
phosphorylates and activates the terminal kinase in the core of
this cascade, AKT (De Meyts, 2000; Figure 3A).
AKT regulates an expansive set of pathways and processes,
only some of which will be discussed in the following section.
AKT (i) regulates translocation of GLUT3, the canonical
neuronal glucose transporter, and of GLUT4, which is also
essential in neurons (Ashrafi et al., 2017), to the plasma
membrane (Grillo et al., 2009; Ferreira et al., 2011). At the
axon terminal and post-synaptic density, the insulin-AKT
pathway (ii) modulates catecholamine release and uptake,
the trafficking of ion-gated channels, and the expression
and localization of neurotransmitter receptors (Chiu et al.,
2008; De Felice and Benedict, 2015). Finally, AKT (iii) is
a potent GSK3β inhibitor (Zhou et al., 2014; Figure 3B).
Each of these mechanisms will be discussed further in the
following subsections.
Lack of Energetic Substrates as an
Exacerbating Factor for AD
Even preclinically, patients with AD show widespread
impairment in glucose metabolic rates (Willette et al., 2015),
a deficiency associated with decreased levels of GLUT1 and
GLUT3 (Liu et al., 2008), which import glucose across the
blood-brain barrier and into neurons, respectively. As the brain
can only use either glucose or ketones, and ketones are not
normally available as a fuel, insulin resistance and the ensuing
decrease in GLUT membrane expression (Figure 3Bi) can
decrease mitochondrial ATP production and all ATP-dependent
maintenance processes that are critical to neuron survival (Fong
et al., 2016; Blonz, 2017).
Animal models support the relevance of GLUT transporter
underexpression in AD, as well as the potential involvement of
dysfunctional Wnt-signaling in this process. For example,
overexpression of GLUT3, which is regulated, in part,
by AKT (Ferreira et al., 2011), helps rescue Drosophila
from the morphological and behavioral features associated
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FIGURE 3 | Insulin resistance exacerbates the pathology of AD. (A) Insulin-AKT Pathway—Insulin binds to the Insulin Receptor (IR) tyrosine kinase, which
autophosphorylates and binds the adaptor protein, Insulin Receptor Substrate (IRS). IRS recruits Phosphoinositide 3-Kinase (PI3K), which phosphorylates PIP2 into
PIP3. PIP3 diffuses along the membrane to activate Phosphoinositide-Dependent Kinase 1 (PDK1), which activates AKT. AKT phosphorylates many enzymes; this
includes inhibiting GSK3β. (B) Insulin Resistance Contributes to Neuropathology—Insulin resistances (i) causes a decrease in AKT-mediated translocation of GLUT
transporters to the membrane. This contributes to the decreased glucose metabolic rate and mitochondrial dysfunctions observed in AD and PD brains. Insulin-AKT
signaling is critical in synaptic transmission, as is Wnt-signaling. Therefore, insulin resistance (ii) may synergize with dysfunctions in Wnt-signaling to decrease
synaptic transmission and synapse integrity. Lastly, insulin resistance (iii) can contribute to hyperinsulinemia and the competitive inhibition of Insulin Degrading
Enzyme (IDE), which also degrades Aβ. Since Aβ inhibits insulin-AKT signaling, either insulin or Aβ can establish a positive feedback loop in which Aβ inhibits insulin
signaling to decrease AKT activity, increase GSK3β activity and, thus, further increase Aβ levels. Dashed and solid lines indicate regulatory mechanisms that are,
respectively, impaired and enhanced in AD.
with Aβ toxicity (Niccoli et al., 2016). Furthermore, in a
mouse model of AD, Nishida et al. (2017) demonstrated
that decreased GLUT1 expression at the blood-brain
barrier was associated with decreased cerebral blood flow,
increased Aβ accumulation, and memory impairment.
Interestingly, Wnt-signaling has been identified as necessary
for GLUT1 expression at the blood-brain barrier (Daneman
et al., 2009), and Pan et al. (2018) showed that inhibition
of GSK3β in AD mice has precisely the opposite effects
to those just described in that GSK3β inhibition increased
cerebral blood flow, prevented Aβ accumulation, and rescued
memory impairment. The complementary findings of the two
mouse studies, in combination with the fact that Wnt ligands
have been observed to increase AKT activity and neuronal
glycolytic rate (Cisternas et al., 2016), hints at the possibility
that dysfunctions in the insulin-AKT and Wnt-signaling
pathways may cooperate to contribute to glucose metabolism
deficiency in AD.
Frontiers in Aging Neuroscience | www.frontiersin.org 8 July 2019 | Volume 11 | Article 184
Norwitz et al. Alzheimer Disease: An Integrated Perspective
Insulin Resistance and Wnt-Signaling in
Synaptic Dysfunction
As insulin regulates the release and reception of
neurotransmitters, cerebral insulin resistance can contribute to
a decrease in synaptic activity and density (Abbott et al., 1999;
Chiu et al., 2008; Lee et al., 2011; De Felice and Benedict, 2015;
Figure 3Bii). In Xenopus tadpoles, the expression of a dominant-
negative IR decreased excitatory post-synaptic potentials and
synaptic density (Chiu et al., 2008). Conversely, activation of
the insulin-AKT axis, by pharmacologically stimulating AKT or
PI3K, increased synaptic density and rescued aberrant synaptic
plasticity in wildtype and AD rodents (Cuesto et al., 2011;
Yi et al., 2018).
At the synapse, the effects of dysfunctional Wnt-signaling
have been shown to be analogous to those of dysfunctional
insulin-signaling. Specifically, blocking the initiation of
Wnt-signaling with DKK1 induced synaptic loss in mice
(Purro et al., 2012; Marzo et al., 2016). Furthermore, as
with AKT activation (Yi et al., 2018), direct pharmacological
activation of Wnt-signaling was sufficient to rescue aberrant
synaptic plasticity (Purro et al., 2012; Marzo et al., 2016). This,
along with the suggestion of crosstalk between the Wnt and
AKT pathways (Palsgaard et al., 2012; Cisternas et al., 2016),
raises the possibility that insulin resistance and dysfunctional
Wnt-signaling may interact to induce synaptic dysfunction in
cognitive decline.
Insulin Resistance and Aβ Can Establish a
Wnt/GSK3β-Dependent Positive
Feedback Loop
Insulin Degrading Enzyme (IDE) is a cytoplasmic and secreted
enzyme that degrades both insulin and Aβ in the human
brain (Qiu et al., 1998; Pérez et al., 2000). Accordingly,
hyperinsulinemia, which is associated with an approximately
two-fold increase in AD risk (Luchsinger et al., 2004), can
competitively inhibit IDE-mediated Aβ degradation (Qiu et al.,
1998; Pérez et al., 2000; Farris et al., 2003; Neth and Craft, 2017).
In turn, Aβ can exacerbate hyperinsulinemia by inhibiting IDE
and competing for IR binding (Pérez et al., 2000; Zhao et al., 2008;
O’Neill, 2013).
But, even in those cases in which cerebral hyperinsulinemia
does not initiate the accumulation of Aβ, a vicious cycle between
Aβ and insulin-AKT signaling can arise once some degree of
amyloid pathology has been established (Figure 3Biii). The De
Felice group has shown that intracerebroventricular infusion
of Aβ oligomers in monkeys disrupts insulin-AKT signaling
in the hippocampus in a TNFα-dependent manner, leading to
memory impairment (Lourenco et al., 2013). In this way, Aβ
releases GSK3β fromAKT-mediated inhibition and, reciprocally,
GSK3β increases Aβ production via the mechanisms displayed
in Figure 1B.
It is also notable that the De Felice group later showed
that intracerebroventricular infusion of Aβ oligomers caused
hypothalamic dysfunction and peripheral insulin resistance in
mice, again in a TNFα-dependent manner. This latter finding,
in conjunction with epidemiological data showing AD increases
an individual’s risk of developing T2DM, suggests yet another
pathological feedback loop in which systemic insulin resistance
increases Aβ production, leading to Aβ-mediated hypothalamic
inflammation that further exacerbates systemic insulin resistance
(Clarke et al., 2015).
The AKT Paradox
Obviously, Figure 3 is a simplification of insulin resistance
pathology in the AD brain. What is not as obvious is how it is
a simplification. Not only are pathways and relationships among
proteins necessarily omitted, but there is also a lack of consensus
on the fundamental nature of key relationships. An important
and illustrative example is that AKT may be either underactive
or overactive in the post-mortem human AD brain (Rickle et al.,
2004; Lee et al., 2009).
While this AKT paradox remains to be resolved, one
hypothesis is that the opposite dysfunctions in AKT activity are
time-dependent. For example, intracellular and extracellular Aβ
may have different effects on AKT activity, with intracellular
Aβ (not explicitly shown in Figure 3B) accumulating well
before extracellular Aβ (Magrané et al., 2005). Intracellular Aβ
can interfere with the interaction between PDK1 and AKT,
contributing to a decrease in AKT activity and to disease
progression (Magrané et al., 2005; Lee et al., 2009). However,
as extracellular Aβ builds up later, a tipping point [possibly one
that is neuron-specific and heterogenous across the brain (Rickle
et al., 2004)] may be reached whereby Aβ binds to IRs and
constitutively overstimulates AKT (Xie et al., 2002; Zhao et al.,
2008; Chiang et al., 2010). Rather than being neuroprotective, this
180◦ flip may be pathogenic in other ways, including saturating
pathway activity, such that the pathway is no longer responsive
to insulin, and inducing mTOR1-mediated IRS inhibition, thus
reinforcing insulin resistance (Zhao et al., 2008; Han et al., 2018).
Moreover, Aβ binding to IRs causes a dramatic migration of IRs
away from neurites to the soma (Zhao et al., 2008), impairing
synaptic integrity and compounding spatial complexity on top of
temporal complexity.
Evidently, the AKT paradox adds a major qualification to
the model presented in Figure 3B, which we presented as is
for the following two reasons: (1) decreased GLUT transporter
expression, decreased synaptic integrity, and increased GSK3β
activity have been more consistently observed in the AD brain
(Leroy et al., 2007; Liu et al., 2008; Llorens-Martín et al., 2014;
Wan et al., 2014) and (2) pharmacological activators of AKT
have demonstrated therapeutic efficacy in Drosophila and mouse
models of AD (Zhang et al., 2016; Yi et al., 2018), whereas
the same cannot be said for AKT inhibitors. It is important to
acknowledge the AKT paradox as a representative example of the
nuance present within even a single model of AD. Appreciating
this nuance will help us better appreciate the true complexity of
AD that arises out of an interrelationship among the models.
AN INTEGRATED PERSPECTIVE AND
CONCLUDING REMARKS
In this review article, we began by summarizing the cellular,
animal, and human work that demonstrate dysfunctional
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FIGURE 4 | Multi-loop model of AD: an integrated perspective on the
Wnt/GSK3β, α-synuclein, and type 3 diabetes hypotheses. (1) GSK3β, also
known as Tau Kinase 1, phosphorylates tau (De Ferrari et al., 2014). (2) In
turn, p-tau may increase GSK3β activity by inducing oxidative stress (Cente
et al., 2006; Feng et al., 2013; Liu et al., 2015). (3) α-synuclein can also
contribute to tau pathology by binding to tau’s microtubule binding domain
(Jensen et al., 1999), recruiting GSK3β to tau, and helping to promote
pathological p-tau aggregation (Ga̧ssowska et al., 2014; Moussaud et al.,
2014). (4) In reciprocation, tau can promote α-synuclein’s phosphorylation by
GSK3β and α-synuclein aggregation (Giasson et al., 2003; Credle et al.,
2015). (5) In addition to facilitating tauopathy, α-synuclein can promote Aβ
production by increasing GSK3β activity (Duka et al., 2009) and β-secretase
levels (Roberts et al., 2017). (6) In turn, Aβ can increase α-synuclein levels
(Majd et al., 2013), possibly by stimulating GSK3β (Yuan et al., 2015). (7) Aβ
can simulate GSK3β activity by inducing the expression of DKK1 and by
binding to and inhibiting Frizzled (Caricasole et al., 2004; Magdesian et al.,
2008). p-AICD, a by-product of Aβ production, can increase GSK3β gene
expression (Chang et al., 2006). (8) GSK3β phosphorylates APP to enable
p-AICD production and to make APP a better substrate for β-secretase (Lee
et al., 2003; Acevedo et al., 2014). GSK3β overactivity and Wnt-signaling
underactivity also increase β-secretase levels, further promoting the
generation of Aβ (Ly et al., 2013; Parr et al., 2015). (9) GSK3β can contribute
to insulin resistance by phosphorylating and inhibiting IRS1 (Lee and Kim,
2007). (10) In turn, insulin-AKT pathway dysfunction can contribute to an
increase in GSK3β activity (Magrané et al., 2005; Lee et al., 2009).
(11) Because insulin and Aβ are both IDE substrates, hyperinsulinemia
prevents Aβ degradation (Qiu et al., 1998; Pérez et al., 2000; Farris et al.,
2003; Neth and Craft, 2017; Folch et al., 2018). (12) Aβ can then further
exacerbate insulin resistance by preventing insulin degradation and by
binding to IRs (Pérez et al., 2000; Zhao et al., 2008; O’Neill, 2013). The above
figure shows only mechanisms whereby these models feedback on one
another and not those additional mechanisms whereby they cooperate to
intensify AD pathology, such as may be the case for glucose transporter
expression and synaptic activity (Chiu et al., 2008; Daneman et al., 2009;
Ferreira et al., 2011; Purro et al., 2012; Marzo et al., 2016).
Wnt-signaling can contribute to the development of AD and
its two pathological hallmarks, Aβ plaques and p-tau tangles.
We next described how the canonical PD-associated protein
α-synuclein may be locked in pathological positive feedback
loops with Aβ and tau. Finally, we discussed some of the
mechanisms by which insulin resistance in the brain, ‘‘type
3 diabetes,’’ may contribute to development and exacerbation of
AD. Throughout each section, we attempted to highlight some
of the ways in which each model interacts with the others.
These interrelationships, summarized in Figure 4, make it clear
that the pathology of AD is not a linear cascade, nor a simple
feedback loop, but rather a network of cross-talking models and
overlapping vicious cycles.
Given the cooperative and reinforced nature of this complex
network, it is no surprise that the prototypical monotherapeutic
approach to AD has reliably failed. Certainly, drugs that target
key nodes within the network, such as GSK3β inhibitors (Noble
et al., 2005; Parr et al., 2012; Licht-Murava et al., 2016) or
AKT activators (Zhang et al., 2016; Yi et al., 2018), have shown
promise in animal models, and this important work affords
us valuable mechanistic insights. However, these pre-clinical
successes generally have not translated into clinical success, at
least not with the same degree of efficacy. This is likely because
animal models harboring distinct AD-causing mutations and
dysfunctions in particular linear pathways do not accurately
recapitulate the complex pathologies underlying sporadic human
AD. In brief, we are proposing that the single-target silver-bullet
approach to AD drug discovery is doomed to fail and that we
may only be able to treat or prevent AD by developing new
multifaceted treatment options.
Further complicating matters, the initial movers of sporadic
human AD are likely highly individual. As examples, only
about half of AD patients present with Lewy Body/α-synuclein
pathology (Yan et al., 2018) and there is evidence to suggest
that diabetes may specifically predispose carriers of the ApoE4
risk allele to develop AD (Zhao et al., 2017; Folch et al., 2018).
If AD is, indeed, composed of many different subtypes, then
even imagining AD as a network of reinforcing positive feedback
loops, as we have done here, underestimates the pathology.
We may not only need multifaceted treatment options, but
personalized ones.
The cost of continuing to simplify AD pathology is a
continuation in the rapidly rising prevalence of AD. It
is, therefore, critical that the global biomedical community
take steps towards thinking more comprehensively about the
mechanisms underlying AD, for only by doing so can we hope
to develop multifaceted, and perhaps one day individualized,
therapies to prevent or treat this devastating disease and reverse
the worldwide neurodegeneration epidemic.
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